Gilead Sciences (GILD +1.4%) keeps the positive momentum churning after announcing it landed EU...


Gilead Sciences (GILD +1.4%) keeps the positive momentum churning after announcing it landed EU approval for its Eviplera treatment for HIV-1 infection - clearing the way for the commercial development of the drug in all 27 member countries. Shares of GILD now stand just a hair below where they traded just prior to the announcement of its blockbuster purchase of Pharmasset (VRUS +0.1%).

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs